MIAMI--(BUSINESS WIRE)--
OPKO Health, Inc. (NASDAQ:OPK) today announced that senior management will present at the Ladenburg Thalmann 2016 Healthcare Conference on September 27th, 2016 at 10:30 AM (ET).
About OPKO Health
OPKO Health, Inc. is a diversified healthcare company that seeks to establish industry-leading positions in large, rapidly growing markets. Our diagnostics business includes BioReference Laboratories, the third-largest clinical laboratory in the U.S. with a core genetic testing business and a 420-person sales force to drive growth and sell new products, such as the 4Kscore® prostate cancer test and the Claros® 1 in office immunoassay platform. Our pharmaceutical business features RAYALDEE®, an FDA-approved treatment for stage 3-4 CKD patients with secondary hyperparathyroidism and vitamin D insufficiency, and VARUBI™ for chemotherapy-induced nausea and vomiting (oral formulation launched by partner Tesaro and IV formulation PDUFA is January 2017). Our biologics products under development are hGH-CTP, a once-weekly human growth hormone for injection (partnered with Pfizer), long-acting Factor VIIa for hemophilia (in Phase 2a) and a long-acting oxyntomodulin for diabetes and obesity (in Phase 1). OPKO has production and distribution assets in several countries abroad, strategic investments and an active business development strategy. More information is available at www.opko.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160919005346/en/
